Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit of TIVICAY in the indication “treatment of Human Immunodeficiency Virus (HIV)-infected adults and adolescents above 12 years of age” is substantial in antiretroviral naïve patients and in experienced patients with prior treatment failure. |
Clinical Added Value
| moderate |
In patients who have no therapeutic options and whose virus is susceptible to dolutegravir :
The Transparency Committee considers that TIVICAY (dolutegravir), in combination with an optimised background regimen, provides a moderate improvement in actual benefit (level III) in terms of immunological and virological efficacy in therapeutic management. |
| minor |
In antiretroviral-naïve or experienced patients whose virus does not have integrase inhibitor (INI) resistance mutations :
The Transparency Committee considers that TIVICAY (dolutegravir) incombination with other antiretrovirals provides a minor improvement in actual benefit (level IV) compared with raltegravir (ISENTRESS) due to having an immunological and virological efficacy that is not inferior to that of raltegravir with a higher genetic barrier to the development of resistance and better ease of use than raltegravir (a single dose versus two daily doses in the case of raltegravir). |
See also
HAS opinions and decisions
05/03/2014
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
wNJUYC5g8sS2T9WZ
Listen
